ArticleCancer chemotherapy and pharmacology2018

Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations.

Xiaojun Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.